The risk of cytotoxic drugs during pregnancy

R. Ramsey-Goldman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Treatment is frequently required before, during, and after pregnancy in women with rheumatic diseases. It is essential that maternal disease be well controlled to ensure the best possible outcome for mother and child. The physician has multiple responsibilities to monitor not only the interactions between the underlying maternal disease and the outcome of pregnancy, but also the impact of the medications on both patients. The limited experience with cytotoxic medications prior to or during pregnancy in women with rheumatic diseases will be addressed in this article.

Original languageEnglish (US)
Pages (from-to)133-135
Number of pages3
JournalScandinavian Journal of Rheumatology, Supplement
Issue number107
StatePublished - 1998

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The risk of cytotoxic drugs during pregnancy'. Together they form a unique fingerprint.

Cite this